TRANSTELLAR: An Open-Label, Long-Term Extension Study of Felzartamab in Kidney Transplant Recipients with Antibody-Mediated Rejection or Microvascular Inflammation (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #INFO22-TH; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; P2, P3 | "Secondary endpoints include the percentage of participants with biopsy-proven histologic resolution, MVI score, percentage of participants with an MVI score of 0, change from baseline in estimated glomerular filtration rate and proteinuria, time to all-cause and death-censored allograft loss, pharmacokinetics, and immunogenicity. TRANSTELLAR will evaluate the long-term safety and durability of felzartamab, further informing its therapeutic potential in AMR and MVI."
Clinical • Antibody-mediated Rejection • Inflammation • Transplantation
|
|
Klemens Budde; Georg Bohmig; Diane Marie Cibrik; Carrie A. Schinstock; Michael Mengel; Elaine F. Reed; Gordon R. Ingle; Rochelle Liverman; Haytham Helmi; Chia-Hsin Ju; Edwin Lam; Curtis D. Holt; Paul Manser; Sundeep Kalapala; Uptal D. Patel; Roslyn B. Mannon
|